Growth through M&A HealthLytix has recently expanded via mergers with CorTechs Labs and Cortechs.ai, signaling a strategic consolidation in medical imaging and neurodegenerative disease screening. This presents an opportunity to engage the unified leadership on cross-sell of advanced imaging analytics, genetics-based risk assessment, and integrated diagnostic tools.

Early Detection Focus The company’s mission centers on improving screening and early detection of cancer and neurodegenerative diseases, suggesting a pathway for sales discussions around RSI-MRI+ and related imaging-genetics solutions that enhance risk prediction and timely diagnosis in clinical workflows.

Small but Targeted With 11-50 employees and revenue in the low single digits, HealthLytix represents a focused, agile account likely receptive to pilot projects, strategic partnerships, and faster decision cycles for implementing advanced imaging and genetic risk tools.

Partnership Potential Past collaborations with CorTechs Labs and Dash Genomics indicate openness to distribution and technology partnerships. There is an opportunity to propose joint go-to-market strategies, co-development of modules, or exclusive distribution arrangements in imaging-genetics domains.

Funding signals Current funding of around four million and annual revenue of roughly one to ten million place HealthLytix in a growth phase where customers that need scalable, ML-driven imaging and genetic risk tools could be targets for multi-year contracts, clinical validation partnerships, or sponsored research deals.